Neurocrine Biosciences

We presented a new post-hoc analysis from the Phase 4 KINECT-PRO™ study at Psych Congress 2025 this past weekend. This study includes patient-reported outcomes related to the physical, social and emotional impact of tardive dyskinesia. Read more in the news release: https://lnkd.in/gfUvJ-sQ

Yesterday we announced the presentation of new data from the Phase 2 SAVITRI™ study of osavampator at Psych Congress 2025. Osavampator is a potential first-in-class investigational treatment being studied as an adjunctive treatment for major depressive disorder. This expands on top-line data shared last year. Read more: https://lnkd.in/gNY7TQ-J

At Psych Congress 2025, we presented new qualitative study findings from interviews and focus groups that offer insight into the functional outcome priorities of patients with schizophrenia, caregivers, and prescribers. Twenty-six functional outcome concepts were included across four domains, including activities of daily living, self-care/appearance/health, relationships/communication and social/leisure. Patients prioritized functional outcomes in the activities of daily living domain, such as doing chores and maintaining a job, while caregivers and prescribers prioritized the self-care/appearance/health domain, which includes medication adherence, attending appointments and personal hygiene. These findings regarding the relative importance of various functional outcomes should be considered when developing novel treatments and care strategies for this serious condition. Check out our pipeline to see what we’re working on: https://lnkd.in/gw-wb6Hn #PsychCongress2025

Neurocrine is proud to support National Advanced Practice Provider Week. APPs are uniquely suited to lead efforts to improve tardive dyskinesia screening practices through their collaborative relationships with patients, care partners and healthcare teams.

Big news on the horizon! We are excited to share that at the upcoming Psych Congress (September 17-21), Neurocrine will present new data from the Phase 2 SAVITRI™ study on osavampator, an investigational drug in development as a potential first-in-class adjunctive treatment to antidepressants for major depressive disorder. Read more about this poster presentation, and our other posters at Psych Congress, here: https://lnkd.in/gnzFP9kM #PsychCongress2025

This month is National Hispanic Heritage Month. We celebrate and recognize the rich cultures, traditions and contributions of the Hispanic and Latino communities.

Our podcast series “TD Dialogues” is now available on Spotify and Apple Podcasts making it easier stay connected to the latest conversations about tardive dyskinesia! In the latest episode, “Facing a Long-Term Care Challenge: A Look at the Impact, Identification, and Treatment of Tardive Dyskinesia,” hear from a dual-certified family nurse practitioner and psychiatric mental health nurse practitioner who shares her perspectives on the impact of tardive dyskinesia in long-term care—both its effects on residents and the challenges it poses to the care team.    Spotify: https://lnkd.in/g6rSvPAy Apple Podcasts: https://lnkd.in/gW8Byvsk  

We’re honored to be recognized as a Great Place to Work™ company. This award is driven by employee feedback and reinforces our commitment to a culture of collaboration, innovation, tenacity, passion, and integrity. Join the team that works each day to relieve suffering for people with great needs: https://lnkd.in/gUudctFv 

We are ranked No. 6 on the 2025 Fortune Best Workplaces in BioPharma™ list. Thank you to our team that drives our caring, collaborative, fun, and supportive culture. Together, we work with one goal in mind – to bring brave science to patients. #BestWorkplaceinBiopharma   https://lnkd.in/g9NHKEvN

We’re sponsoring a medical symposium in Las Vegas during the Gerontological Advanced Practice Nurses Association (GAPNA) annual conference. Join us with speakers Tana Whitt, MSN, PMHNP-BC and Charissa Duffy, DNP, MSN, PMHNP-BC, for an interactive, case-based session that examines the differentiation of drug-induced movement disorders and the clinical presentation of tardive dyskinesia in older adults. The speakers have been compensated by Neurocrine Biosciences. This presentation is not certified for continuing medical education credit.